Literature DB >> 9440814

Overexpression of mouse follistatin causes reproductive defects in transgenic mice.

Q Guo1, T R Kumar, T Woodruff, L A Hadsell, F J DeMayo, M M Matzuk.   

Abstract

Follistatin is an activin-binding protein that can act as an activin antagonist in vitro. Follistatin also binds heparin sulfate proteoglycans and may function as a reservoir for activins in vivo. In the mouse, follistatin mRNA is first detected in the deciduum on embryonic day 5.5 and later in the developing hindbrain, somites, vibrissae, teeth, epidermis, and muscle. We have previously shown that follistatin-deficient mice have numerous embryonic defects including shiny, taut skin, growth retardation, and cleft palate leading to death within hours of birth. To further define the roles of follistatin during mammalian reproduction and development, we created gain-of-function mutant mice in which mouse follistatin is overexpressed. The mouse metallothionein (MT)-I promoter was placed upstream of the six-exon mouse follistatin (FS) gene. To distinguish wild-type and transgenic follistatin mRNA, the 3'-untranslated region of the mouse follistatin gene was replaced with the SV40 untranslated and polyA sequences. Three male and two female founder transgenic mice were produced, were fertile, and transmitted the transgene to offspring. Northern blot analysis demonstrated that the transgene mRNA was expressed at varying levels in the livers of offspring from four of five of the transgenic lines and was expressed in the testes in all five lines. In MT-FS line 4, which had the highest expression of the transgene mRNA in the liver, the transgene transcripts were also present in multiple other tissues. Phenotypically, the MT-FS transgenic lines had defects in the testis, ovary, and hair. Mice from MT-FS lines 7 and 10 had slightly decreased testis size, whereas mice from lines 4, 5, and 9 had much smaller testes and shiny, somewhat irregular, fur. Histological analysis of the adult testes from line 5 and 9 males showed variable degrees of Leydig cell hyperplasia, an arrest of spermatogenesis, and seminiferous tubular degeneration leading to infertility. Female transgenic mice from lines 4 and 9 had thin uteri and small ovaries due to a block in folliculogenesis at various stages. Many of the line 9 female mice eventually became infertile, and all of the line 4 female mice were infertile. Suppressed serum FSH levels were seen in only the line 4 transgenic male and female mice, the line with widespread expression of the transgene. Serum FSH levels were not significantly different in gonadectomized wild-type and line 5 transgenic male mice despite high levels of the follistatin transgene mRNA in the liver of these transgenic mice. These results suggest that follistatin exerts its effects at the levels of the gonads and pituitary as a local regulator of activin and possibly other transforming growth factor-beta family members.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9440814     DOI: 10.1210/mend.12.1.0053

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  39 in total

1.  Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts.

Authors:  Darcie D Seachrist; Emhonta Johnson; Christianne Magee; Colin M Clay; James K Graham; D N Rao Veeramachaneni; Ruth A Keri
Journal:  Biol Reprod       Date:  2012-08-23       Impact factor: 4.285

2.  Activin modulates the transcriptional response of LbetaT2 cells to gonadotropin-releasing hormone and alters cellular proliferation.

Authors:  Hao Zhang; Janice S Bailey; Djurdjica Coss; Bo Lin; Rie Tsutsumi; Mark A Lawson; Pamela L Mellon; Nicholas J G Webster
Journal:  Mol Endocrinol       Date:  2006-06-13

Review 3.  Fetal and early postnatal environmental exposures and reproductive health effects in the female.

Authors:  Teresa K Woodruff; Cheryl Lyn Walker
Journal:  Fertil Steril       Date:  2008-02       Impact factor: 7.329

4.  Smad4 overexpression causes germ cell ablation and leydig cell hyperplasia in transgenic mice.

Authors:  Anita Narula; Signe Kilen; Eva Ma; Jessica Kroeger; Erwin Goldberg; Teresa K Woodruff
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 5.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

6.  Genetics of polycystic ovary syndrome.

Authors:  N Prapas; A Karkanaki; I Prapas; I Kalogiannidis; I Katsikis; D Panidis
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 7.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 8.  The biology of activin: recent advances in structure, regulation and function.

Authors:  Yin Xia; Alan L Schneyer
Journal:  J Endocrinol       Date:  2009-03-09       Impact factor: 4.286

9.  Transgenic mouse technology: principles and methods.

Authors:  T Rajendra Kumar; Melissa Larson; Huizhen Wang; Jeff McDermott; Illya Bronshteyn
Journal:  Methods Mol Biol       Date:  2009

10.  Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo.

Authors:  Elspeth Gold; Niti Jetly; Moira K O'Bryan; Sarah Meachem; Deepa Srinivasan; Supreeti Behuria; L Gabriel Sanchez-Partida; Teresa Woodruff; Shelley Hedwards; Hong Wang; Helen McDougall; Victoria Casey; Birunthi Niranjan; Shane Patella; Gail Risbridger
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.